Weight loss of 14.5%! After the failure of its Alzheimer's trial, Novo Nordisk released positive data on a new weight-loss drug, boosting its stock price.
```
Clinical trial data released by Novo Nordisk for the new-generation diabetes drug amycretin shows that the drug achieves significant weight loss while lowering blood sugar, giving a boost to the Danish pharmaceutical company whose market value has halved this year.
On Tuesday, trial results released by Novo Nordisk showed that